Given the prevalence of hematological conditions, surgeries, and trauma incidents, hemostats—therapeutics designed to control and arrest bleeding—are an important tool in patient care. The prophylactic and therapeutic use of hemostats markedly enhances survival rates and improves the overall quality of life of patients suffering from these conditions. Since their inception in the 1960s, hemostats have witnessed remarkable progress in terms of the active ingredients utilized, therapeutic outcomes, demonstrated efficacy, and the storage stability. In this review, we provide a comprehensive analysis of commercially available hemostats approved by the FDA, along with newer investigative hemostats currently in active clinical trials. We delve into the modality of active ingredients, route of administration, formulation type, and disease indications of these approved and investigative hemostats. Further, we analyze the trends observed in the hemostat actives for Hemophilia A and B, concluding with insights into the emerging patterns and noteworthy developments to watch for in this dynamic field.

中文翻译：

---

诊所中的止血剂

鉴于血液病、手术和创伤事件的普遍存在，止血剂（旨在控制和阻止出血的治疗药物）是患者护理的重要工具。止血剂的预防和治疗用途可显着提高患有这些疾病的患者的生存率并改善其整体生活质量。自 20 世纪 60 年代问世以来，止血剂在活性成分、治疗效果、疗效和储存稳定性方面取得了显着进步。在这篇综述中，我们对 FDA 批准的市售止血剂以及目前正在进行临床试验的新型研究止血剂进行了全面分析。我们深入研究了这些已批准和正在研究的止血剂的活性成分形式、给药途径、制剂类型和疾病适应症。此外，我们分析了血友病 A 和 B 的止血活性剂中观察到的趋势，最后深入了解了这个动态领域中出现的模式和值得注意的发展。